Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Dompe Farmaceutici SpA | 21 |
| 2 | GSK PLC | 20 |
| 3 | Pulmatrix Inc | 20 |
| 4 | Utah System of Higher Education | 8 |
| 5 | Centre National de la Recherche Scientifique | 7 |
| 6 | Duke University | 7 |
| 7 | BASF SE | 5 |
| 8 | Boston Children's Hospital | 5 |
| 9 | Washington University in St. Louis | 4 |
| 10 | AstraZeneca PLC | 3 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 225 |
| 2 | A61K | Medicinal preparations | 194 |
| 3 | C07D | Heterocyclic compounds | 112 |
| 4 | C07K | Peptides | 46 |
| 5 | C12N | Microorganisms, enzymes | 40 |
| 6 | G01N | Investigating / analysing materials | 29 |
| 7 | C07F | Organometallic compounds | 26 |
| 8 | A01K | 14 | |
| 9 | C12Q | Measuring/testing involving enzymes | 13 |
| 10 | A61B | 12 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Novel application of TRPV4 agonist GSK1016790A | 2020 | 3 | |
| Application of GSK1016790A in preparation of medicine for treating or relieving diabetic enteropathy | 2024 | 0 | |
| Application of GSK1016790A in preparing medicine for treating or relieving diabetic enteropathy | 2022 | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 7 |
| 2017 | 15 |
| 2018 | 15 |
| 2019 | 15 |
| 2020 | 11 |
| 2021 | 9 |
| 2022 | 4 |
| 2023 | 11 |
| 2024 | 5 |
| 2025 | 3 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | David Križaj | University of Utah | 7 |
| 2 | Yimei Du | Union Hospital | 6 |
| 3 | Oleg Yarishkin | University of Utah | 6 |
| 4 | Kevin S. Thorneloe | GlaxoSmithKline (United States) | 4 |
| 5 | Weixing Xu | Nanjing Medical University | 4 |
| 6 | Kelli M. Wilson | National Center for Advancing Translational Sciences | 3 |
| 7 | Chunfeng Wu | Second Affiliated Hospital of Nanjing Medical University | 3 |
| 8 | Thomas Voets | KU Leuven | 3 |
| 9 | Matthew D. Hall | National Institutes of Health | 3 |
| 10 | Nicholas A. Veldhuis | The University of Melbourne | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Elementary Ca 2+ Signals Through Endothelial TRPV4 Channels Regulate Vascular Function | 2012 | 552 | Nitric Oxide and Endothelin Effects |
| Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis | 2010 | 412 | Urinary Bladder and Prostate Research |
| N-((1 S)-1-{[4-((2 S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a Novel and Potent Transient Receptor Potential Vanilloid 4 Channel Agonist Induces Urinary Bladder Contraction and Hyperactivity: Part I | 2008 | 408 | Urinary Bladder and Prostate Research |
| TRPV4-mediated endothelial Ca2+ influx and vasodilation in response to shear stress | 2009 | 337 | Ion Channels and Receptors |
| Systemic Activation of the Transient Receptor Potential Vanilloid Subtype 4 Channel Causes Endothelial Failure and Circulatory Collapse: Part 2 | 2008 | 299 | Heart Rate Variability and Autonomic Control |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of GSK1016790A?
Which organizations hold the most patents related to GSK1016790A?
What is the primary mechanism of action studied for GSK1016790A?
Which researchers have published the most papers on GSK1016790A?
What has been the patent filing trend for GSK1016790A in recent years?